SLC28A1 and cancer: In addition to the loss of CNT1 expression identified in solid tumors and leukemias, where nucleoside analogs are used as first-line treatment agents[115,118,119], several genetic variants have been associated with a worse outcome in patients with different types of cancer [Figure 3 and Table 3].